AU2017230098B2 - Compounds and methods for modulating bruton's tyrosine kinase - Google Patents

Compounds and methods for modulating bruton's tyrosine kinase Download PDF

Info

Publication number
AU2017230098B2
AU2017230098B2 AU2017230098A AU2017230098A AU2017230098B2 AU 2017230098 B2 AU2017230098 B2 AU 2017230098B2 AU 2017230098 A AU2017230098 A AU 2017230098A AU 2017230098 A AU2017230098 A AU 2017230098A AU 2017230098 B2 AU2017230098 B2 AU 2017230098B2
Authority
AU
Australia
Prior art keywords
unsubstituted
substituted
independently
nhc
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017230098A
Other languages
English (en)
Other versions
AU2017230098A1 (en
Inventor
Anne-Marie Beausoleil
Ryan Hudson
Richard A. Miller
Erik Verner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angel Pharmaceutical Co Ltd
Original Assignee
Angel Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angel Pharmaceutical Co Ltd filed Critical Angel Pharmaceutical Co Ltd
Publication of AU2017230098A1 publication Critical patent/AU2017230098A1/en
Assigned to Angel Pharmaceutical Co., Ltd. reassignment Angel Pharmaceutical Co., Ltd. Request for Assignment Assignors: CORVUS PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2017230098B2 publication Critical patent/AU2017230098B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2017230098A 2016-03-11 2017-03-10 Compounds and methods for modulating bruton's tyrosine kinase Active AU2017230098B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662307399P 2016-03-11 2016-03-11
US62/307,399 2016-03-11
US201662342004P 2016-05-26 2016-05-26
US62/342,004 2016-05-26
PCT/US2017/021966 WO2017156495A1 (en) 2016-03-11 2017-03-10 Compounds and methods for modulating bruton's tyrosine kinase

Publications (2)

Publication Number Publication Date
AU2017230098A1 AU2017230098A1 (en) 2018-09-20
AU2017230098B2 true AU2017230098B2 (en) 2021-03-25

Family

ID=59789888

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017230098A Active AU2017230098B2 (en) 2016-03-11 2017-03-10 Compounds and methods for modulating bruton's tyrosine kinase

Country Status (12)

Country Link
US (2) US10870652B2 (https=)
EP (1) EP3426637B1 (https=)
JP (1) JP6972002B2 (https=)
KR (1) KR102416971B1 (https=)
CN (2) CN109071455B (https=)
AU (1) AU2017230098B2 (https=)
ES (1) ES2912465T3 (https=)
IL (1) IL261583A (https=)
MX (1) MX388026B (https=)
PL (1) PL3426637T3 (https=)
WO (1) WO2017156495A1 (https=)
ZA (1) ZA201805951B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102416971B1 (ko) * 2016-03-11 2022-07-04 엔젤 파마슈티칼 컴퍼니, 리미티드 브루톤형 티로신 키나제를 조절하기 위한 화합물 및 방법
JOP20190113A1 (ar) * 2016-11-18 2019-05-15 Biocad Joint Stock Co مثبطات بروتون تيروزين كيناز
KR102627756B1 (ko) * 2017-03-22 2024-01-23 쑤저우 바이지부공 파마수티컬 테크널러지 컴퍼니 리미티드 브루톤 타이로신 키나제 억제제
KR102384924B1 (ko) * 2017-07-12 2022-04-08 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
CN108191871B (zh) * 2018-01-02 2020-02-18 成都倍特药业有限公司 新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用
CN111662232B (zh) * 2019-03-06 2022-08-02 中国科学院上海药物研究所 具有2h-吲唑结构的小分子化合物及其合成和应用
TWI762939B (zh) 2019-05-31 2022-05-01 大陸商海思科醫藥集團股份有限公司 Btk抑制劑環衍生物及其製備方法和藥學上的應用
WO2020252397A1 (en) * 2019-06-12 2020-12-17 Baylor College Of Medicine Small molecule proteolysis-targeting chimeras and methods of use thereof
HUE065965T2 (hu) * 2019-09-26 2024-06-28 Jumbo Drug Bank Co Ltd 4-fluor-1H-pyrazolo[3,4-C]piridin-származékok mint szelektív bruton-tirozinkináz (BTK) inhibitorok a B-sejtes limfóma és autoimmun betegségek kezelésére
CN114437078A (zh) * 2020-11-03 2022-05-06 海思科医药集团股份有限公司 一种降解btk的氘代物及其在医药上的应用
CN117377675A (zh) * 2021-06-01 2024-01-09 正大天晴药业集团股份有限公司 含有并环或螺环的布鲁顿酪氨酸激酶降解剂
WO2023009785A1 (en) * 2021-07-29 2023-02-02 Cedilla Therapeutics, Inc. Tead inhibitors and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013010136A2 (en) * 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368631A1 (en) * 1999-03-26 2000-10-05 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
SE0301906D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
HRP20110892T1 (hr) * 2005-12-13 2011-12-31 Schering Corporation Policiklični derivati indazola koji su inhibitori erk
US7659283B2 (en) 2006-02-14 2010-02-09 Vertex Pharmaceuticals Incorporated Pyrrolo [3,2-C] pyridines useful as inhibitors of protein kinases
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
US20120101114A1 (en) * 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
ES2660418T3 (es) * 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
US8633318B2 (en) 2008-09-16 2014-01-21 Proximagen Ltd Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
KR101301533B1 (ko) 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
JP5985658B2 (ja) 2012-01-31 2016-09-06 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． ブルトンチロシンキナーゼ阻害薬としての環状分子
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
US9795604B2 (en) 2013-10-25 2017-10-24 Pharmacyclics Llc Methods of treating and preventing graft versus host disease
WO2015124570A1 (en) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
EP3414234B1 (en) * 2015-10-14 2022-06-29 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
US10662187B2 (en) * 2016-01-21 2020-05-26 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
KR102416971B1 (ko) * 2016-03-11 2022-07-04 엔젤 파마슈티칼 컴퍼니, 리미티드 브루톤형 티로신 키나제를 조절하기 위한 화합물 및 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013010136A2 (en) * 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase

Also Published As

Publication number Publication date
IL261583A (en) 2018-10-31
KR20180133415A (ko) 2018-12-14
EP3426637B1 (en) 2022-02-09
ZA201805951B (en) 2020-12-23
ES2912465T3 (es) 2022-05-26
US20190106423A1 (en) 2019-04-11
EP3426637A1 (en) 2019-01-16
WO2017156495A8 (en) 2018-09-27
EP3426637A4 (en) 2019-09-18
CN109071455A (zh) 2018-12-21
US10870652B2 (en) 2020-12-22
US11306099B1 (en) 2022-04-19
WO2017156495A1 (en) 2017-09-14
MX2018010971A (es) 2019-03-28
NZ745927A (en) 2024-05-31
AU2017230098A1 (en) 2018-09-20
PL3426637T3 (pl) 2022-05-30
CA3017567A1 (en) 2017-09-14
JP2019507793A (ja) 2019-03-22
CN109071455B (zh) 2022-08-02
JP6972002B2 (ja) 2021-11-24
CN115746000A (zh) 2023-03-07
KR102416971B1 (ko) 2022-07-04
MX388026B (es) 2025-03-19

Similar Documents

Publication Publication Date Title
AU2017230098B2 (en) Compounds and methods for modulating bruton's tyrosine kinase
AU2017358901B2 (en) Compounds and methods for modulating interleukin-2-inducible T-cell kinase
ES2609087T3 (es) Derivado de dihidropirazolopirimidinona
EP3179991B1 (en) Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
TWI714590B (zh) 吡啶並［３，４－ｄ］嘧啶衍生物及其藥學上可被許可的鹽
US10980755B2 (en) LRH-1 modulators
CA3154073A1 (en) Isoindolinone and indazole compounds for the degradation of egfr
EP2947086A1 (en) Novel fused pyrimidine compound or salt thereof
US20240336643A1 (en) Bifunctional compounds that degrade alk and uses thereof
AU2022405474A1 (en) E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications
US20220144826A1 (en) Heteroaromatic and Heterobicyclic Aromatic Derivatives for the Treatment of Ferroptosis-Related Disorders
JP2024505711A (ja) 窒素含有多環式縮合環系化合物、その医薬組成物、製造方法及び用途
US20240150340A1 (en) CDK Inhibitors And Their Use As Pharmaceuticals
US20210269442A1 (en) Fused ring derivative used as fgfr4 inhibitor
CA3021324A1 (en) Erbb inhibitors and uses thereof
CA3115595A1 (en) Further heteroaromatic compounds having activity against rsv
WO2016022839A1 (en) Modulators of ire1
US20250186437A1 (en) Carboline compounds and use thereof
AU2016341884B2 (en) Piperazinyl norbenzomorphan compounds and methods for using the same
CA3017567C (en) Compounds and methods for modulating bruton's tyrosine kinase
US20200079793A1 (en) Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor
HK1262897A1 (en) Compounds and methods for modulating bruton's tyrosine kinase
HK1262897B (en) Compounds and methods for modulating bruton's tyrosine kinase
WO2024104968A1 (en) Pyrazolopyrrolopyridazines and their uses as pdgfr inhibitors
HK40016226A (en) Compounds for modulating adenosine a2b receptor and adenosine a2a receptor

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ANGEL PHARMACEUTICAL CO., LTD.

Free format text: FORMER APPLICANT(S): CORVUS PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)